SEP
CSTL icon

Signature Equity Partners’s Castle Biosciences CSTL Stock Holding History

Signature Equity Partners’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16
Closed -$393 – 1598
2026
Q1 		$393 Hold
16
– – ﹤0.01% 1410
2025
Q4 		$622 Buy
+16
New +$516 ﹤0.01% 1497

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Signature Equity Partners's CSTL Position: Q2 2026 in Review

Signature Equity Partners sold out of Castle Biosciences (CSTL) in Q2 2026, closing a stake of 16 shares — an estimated $393 sold.

Signature Equity Partners first reported a position in CSTL in Q4 2025 and held it in 2 quarters. The position peaked at $622 in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Signature Equity Partners reported no remaining Castle Biosciences position as of Q2 2026 after selling out during the quarter.
  • Signature Equity Partners sold 16 Castle Biosciences shares in Q2 2026, an estimated $393.
  • Signature Equity Partners first reported a position in Castle Biosciences in Q4 2025 and held it in 2 quarters.
  • Signature Equity Partners's Castle Biosciences position peaked at $622 in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.